Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A 16-week double blind, placebo-controlled investigation of escitalopram in adolescents with
depression and/or anxiety with a family history of Bipolar Disorder. Subjects will be
evaluated using semi-structured diagnostic interviews and symptom ratings, participate in a
MRI scan and then randomized to treatment. Following randomization, high-risk youth will have
visits every week for the first 4 weeks of treatment then biweekly up to 16 weeks during
which time tolerability and ratings will be performed. MRI scan will be repeated at week 4.